This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: The University of Texas System. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Janos Roszik: Innovator in Cancer Research
Introduction
Janos Roszik is a prominent inventor based in Houston, TX (US), known for his significant contributions to cancer research. With a focus on uveal melanoma, he has developed innovative methods that aim to improve prognostic assessments and therapeutic strategies for this aggressive form of cancer. His work has led to the filing of 2 patents that highlight his expertise in the field.
Latest Patents
One of Janos Roszik's latest patents is titled "Use of SDHA as a prognostic marker and therapeutic target in uveal melanoma." This patent outlines methods for identifying the expression of SDHA, MIF, and the status of monosomy 3 or disomy 3 in samples. These methods are crucial for determining high-risk melanoma cases and assessing sensitivity to oxidative phosphorylation inhibitors. Additionally, the patent provides treatment methods for monosomy 3 uveal melanoma by administering an SDHA inhibitor alongside an oxidative phosphorylation inhibitor.
Another significant patent is "HLA-restricted VGLL1 peptides and use thereof in promoting an immune response in a subject." This patent presents tumor-antigen VGLL1 specific peptides and describes methods for generating VGLL1-specific T cells. These T cells can be utilized for cancer treatment, and the VGLL1-specific peptides may also serve as a vaccine, showcasing the potential for immunotherapy in cancer care.
Career Highlights
Janos Roszik is affiliated with the University of Texas System, where he conducts his research and develops his innovative ideas. His work is characterized by a commitment to advancing cancer treatment and improving patient outcomes through scientific discovery.
Collaborations
Janos collaborates with esteemed colleagues such as Chandrani Chattopadhyay and Gregory Lizée, who contribute to his research efforts and enhance the impact of his work in the field of oncology.
Conclusion
Janos Roszik's contributions to cancer research through his patents and collaborations reflect his dedication to improving therapeutic options for patients with uveal melanoma. His innovative approaches hold promise for advancing the understanding and treatment of this challenging disease.